Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 107291

Result Summary for 107291

Result Summary

Protocol ID:	107291
Clinical Study ID:	107291
Official Title:	A phase IIIb, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly in healthy female subjects aged 15 – 25 years
Phase:	phase 3
Study Indications or Diseases:	Infections, Papillomavirus
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638. Kim CS et al. (2011) Human Papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: Immunogenicity and Safety in 15–25 year old healthy Korean women. J Gynecol Oncol. 22(2):67-75.